Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 3/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434366 | 0.88 | — | — | |
| SCHEMBL5226655 | 0.79 | SLC2A1 (0.40) | MAPK14 | |
| SCHEMBL3434765 | 0.73 | ALDH1A2 (0.32) | BRAF | |
| SCHEMBL3421116 | 0.72 | MAPK14 (0.37) | MAPK14BRAFCDK4CDK2 | |
| SCHEMBL1642029 | 0.72 | CDK2 (0.48) | MAPK14BRAFCDK4CDK2TGFBR1 | |
| SCHEMBL3422428 | 0.71 | MAPK14 (0.48) | MAPK14CDK4CDK2 | |
| SCHEMBL1641904 | 0.70 | BRAF (0.51) | MAPK14BRAFCDK4CDK2 | |
| SCHEMBL30410597 | 0.68 | PTGS2 (0.51) | CDK2TGFBR1KCNH2 | |
| SCHEMBL29039439 | 0.68 | PTGS2 (0.51) | CDK2TGFBR1KCNH2 | |
| SCHEMBL1640578 | 0.68 | CDK2 (0.53) | CDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231625-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |